

List of Figures

2.1 Long term complications of Diabetes	12
2.2 Anomers of D-glucose present in aqueous solution	15
2.3 Absorption profile of Intralipid, fat, hemoglobin, skin melanin and water in NIR region	23
2.4 Commercially available 10%, 20% and 30% Intralipid™ medium	27
2.5 (A). Finger phantom and (B). Potential photon path in phantom	31
3.1 Preparation of Intralipid™ tissue phantom and its different constituents	51
3.2 Block diagram of our <i>in-vitro</i> technique based prototype (MUS-IR) unit	54
3.3 Absorption profile of main intracellular absorbers	57
3.4 Absorption pattern of oxyhemoglobin and reduced hemoglobin from 550 nm to 1000 nm respectively	57
3.5 Absorption characteristics of glucose dissolved in water within the NIR and IR spectral region	58
3.6 Absorption profile of water and glucose in water at 800 nm to 1400 nm regions.	58
3.7 Mini-spectrometer of Avantes Inc., USA	59
3.8 Absorption characteristics of 10% Dextrose (glucose)-distill water between 300 nm to 1050 nm respectively	59
3.9 (a): Digital spectrophotometer of M.S Electronics Pvt. Ltd. (India), (b): Absorption spectra of glucose in distill water in the range between 900 nm to 980 nm	61
3.10 Amplitude modulated signal waveform	63
3.11 Amplitude modulated waveform characteristics as provided to the sample holder	64
3.12 The output waveform pattern from the USR unit as recorded by DSO	65
3.13 Sample holder of our <i>in-vitro</i> technique based prototype unit	65
3.14 Square wave signal	66

3.15 Maximum spectral intensity distribution of the IR LED used in our prototype unit	67
3.16 Peak-to-peak amplitude spectrum (in FFT domain) examined at 940 nm with different glucose concentration solutions	68
3.17 Peak-to-peak amplitude spectrum (in FFT domain) assessed at 940 nm from Intralipid™ phantom sample with different glucose concentrations	69
3.18 The output signal acquired from the human blood plasma sample mixed with Intralipid™ phantom medium	70
3.19 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with healthy human blood plasma samples as obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	73
3.20 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with diabetic human blood plasma samples as obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	75
3.21 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with healthy human blood serum samples as obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	76
3.22 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with diabetic human blood serum samples as obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	77
3.23 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with healthy human whole blood samples as	

obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	79
3.24 (a-c): The peak-to-peak amplitude in FFT domain relationship with the different glucose concentrations present in different volumes (1 ml, 2 ml, and 3 ml) of Intralipid™ phantom samples mixed with diabetic human whole blood samples as obtained from the <i>in-vitro</i> samples of the study subjects during fasting, postprandial and random stages respectively	80
3.25 (a): Shows the observed signal (b) its corresponding peak amplitude in FFT domain of the Intralipid™ sample as a blank in absence of ultrasound in MUS-IR unit	83
3.26 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of Intralipid™ sample as a blank in presence of ultrasound in MUS-IR unit	83
3.27 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of fasting plasma mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	84
3.28 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of postprandial plasma mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	85
3.29 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of fasting serum mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	86
3.30 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of postprandial serum mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	86
3.31 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of fasting whole blood mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	87
3.32 (a): Shows the observed signal (b) its corresponding peak amplitude spectrum in FFT domain of postprandial whole blood mixed Intralipid™ sample in presence of ultrasound in MUS-IR unit	87

3.33 Our <i>In-vitro</i> technique based prototype (MUS-IR) unit	90
3.34 Our <i>in-vitro</i> technique based prototype unit for Predicted Blood Glucose Level measurement in human blood samples	91
3.35 Clarke Error Grid plot	92
3.36 Parkes Error Grid plot	93
4.1 Flowchart depicting the algorithmic concept	99
4.2 Shows mathematical function of absolute value of blank (0 mg) dextrose with Intralipid™ phantom (tissue based)	103
4.3 Shows mathematical function of square value of blank (0 mg) dextrose with Intralipid™ phantom (tissue based)	103
4.4 Shows mathematical function of absolute value of (500 mg) dextrose with Intralipid™ phantom (tissue based)	104
4.5 Shows mathematical function of square value (500 mg) dextrose with Intralipid™ phantom (tissue based)	104
4.6 Shows mathematical function of absolute value of (1000 mg) dextrose with Intralipid™ phantom (tissue based)	105
4.7 Shows mathematical function of square value (1000 mg) dextrose with Intralipid™ phantom (tissue based)	105
4.8 Shows mathematical function of absolute value of (1500 mg) dextrose with Intralipid™ phantom (tissue based)	106
4.9 Shows mathematical function of square value (1500 mg) dextrose with Intralipid™ phantom (tissue based)	106
4.10 Shows mathematical function of absolute values of different concentration of dextrose with Intralipid™ phantom (tissue based) (w/v)	108
4.11 Shows mathematical function of square values of different concentration of dextrose with Intralipid™ phantom (tissue based) (w/v)	109
4.12 Shows <i>in-vitro</i> values of different concentration of dextrose with Intralipid™ phantom (tissue based) (w/v)	109

5.1 OGTT response curve of the study subjects (1 to 3); error bars indicate ± 5 percentage error	115
5.2 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 03 human subject's blood plasma mixed with Intralipid™ phantom samples	115
5.3 Parkes error grid analysis based plot for reference and predicted blood glucose measurement as obtained from 03 human subject's blood plasma mixed with Intralipid™ phantom samples	116
5.4 OGTT response curve of the study subjects (1 to 5) on 1 st day; error bars indicate ± 5 percentage error	121
5.5 OGTT response curve of the study subjects (6 to 10) on 2 nd day; error bars indicate ± 5 percentage error	122
5.6 OGTT response curve of the study subjects (11 to 15) on 3 rd day; error bars indicate ± 5 percentage error	122
5.7 OGTT response curve of the study subjects (16 to 20) on 4 th day; error bars indicate ± 5 percentage error	123
5.8 OGTT response curve of the study subjects (21 to 25) on 5 th day; error bars indicate ± 5 percentage error	123
5.9 OGTT response curve of the study subjects (26 to 30) on 6 th day; error bars indicate ± 5 percentage error	124
5.10 Fasting, postprandial and random stage response bars of the study subjects (01 to 15) on 1 st day; error bars indicate ± 5 percentage error	125
5.11 Fasting, postprandial and random stage response bars of the study subjects (16 to 30) on 2 nd day; error bars indicate ± 5 percentage error	125
5.12 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject's blood plasma mixed with Intralipid™ phantom samples	126
5.13 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject's blood plasma mixed with Intralipid™ phantom samples	127

5.14 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject's blood plasma mixed with Intralipid™ samples	130
5.15 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject's blood plasma mixed with Intralipid™ phantom samples	131
5.16 Normal human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (1 to 5) on 1 st day; error bars indicate ±5 percentage error	137
5.17 Diabetic human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (6 to 10) on 1 st day; error bars indicate ±5 percentage error	137
5.18 Normal human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (11 to 15) on 2 nd day; error bars indicate ±5 percentage error	138
5.19 Diabetic human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (16 to 20) on 2 nd day; error bars indicate ±5 percentage error	138
5.20 Normal human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (21 to 25) on 3 rd day; error bars indicate ±5 percentage error	139
5.21 Diabetic human blood serum mixed with Intralipid™ phantom samples response bars of the study subjects (26 to 30) on 3 rd day; error bars indicate ±5 percentage error	139
5.22 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 15 normal and 15 diabetic human subject's blood serum mixed with Intralipid™ phantom samples	140
5.23 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 15 normal and 15 diabetic human subject's blood serum mixed with Intralipid™ phantom samples	141

5.24 Fasting, postprandial and random stage response bars of the study subjects (01 to 15) on 1 st day; error bars indicate ± 5 percentage error	144
5.25 Fasting, postprandial and random stage response bars of the study subjects (16 to 31) on 2 nd day; error bars indicate ± 5 percentage error	145
5.26 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 31 human subject's blood serum mixed with Intralipid TM phantom samples	145
5.27 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 31 human subject's blood serum mixed with Intralipid TM phantom samples	146
5.28 Healthy human whole blood mixed with Intralipid TM phantom samples response bars of the study subjects (1 to 5); error bars indicate ± 5 percentage error	151
5.29 Diabetic human whole blood mixed with Intralipid TM phantom samples response bars of the study subjects (6 to 10); error bars indicate ± 5 percentage error	152
5.30 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed Intralipid TM phantom samples	153
5.31 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed Intralipid TM phantom samples	154
5.32 Fasting, postprandial and random stage response bars of the study subjects (01 to 11) on 1 st day; error bars indicate ± 5 percentage error	157
5.33 Fasting, postprandial and random stage response bars of the study subjects (12 to 23) on 2 nd day; error bars indicate ± 5 percentage error	157
5.34 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 23 human subject's whole blood mixed with Intralipid TM phantom samples	158
5.35 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 23 human subject's whole blood mixed Intralipid TM phantom samples	159

5.36 Category I: Random stage based whole blood mixed with Intralipid™ phantom samples response bars of the study subjects (1 to 10); error bars indicate ±5 percentage error	165
5.37 Category II: Random stage based whole blood mixed with Intralipid™ phantom samples response bars of the study subjects (11 to 20); error bars indicate ±5 percentage error	165
5.38 Category III: Random stage based whole blood mixed with Intralipid™ phantom samples response bars of the study subjects (21 to 30); error bars indicate ±5 percentage error	166
5.39 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category I: random stage examination	167
5.40 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category I: random stage examination	168
5.41 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category II: random stage examination	169
5.42 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category II: random stage examination	170
5.43 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category III: random stage examination	172
5.44 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 10 human subject's whole blood mixed with Intralipid™ phantom samples in Category III: random stage examination	173
5.45 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject's whole blood mixed with Intralipid™ phantom samples in Category I, II and III: random stage examination	174

5.46 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from 30 human subject’s whole blood mixed with Intralipid™ phantom samples in Category I, II and III: Random stage examination	175
5.47 Variations in voltage amplitude values with increase in concentration of dextrose (glucose) in different types of tissue optical phantom mediums	180
6.1 Deming Regression based analysis	188
6.2 Mountain Plot based analysis	193
6.3 Bland-Altman Plot based analysis	195
6.4 The scatter diagram of Reference and Predicted Blood Glucose Levels	198
6.5 The scatter diagram of Reference and Predicted Blood Glucose Levels	199
6.6 Clarke Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from overall human subject’s blood samples mixed with Intralipid™ phantom	203
6.7 Parkes Error Grid analysis based plot for reference and predicted blood glucose measurement as obtained from overall human subject’s blood samples mixed with Intralipid™ phantom	205
